1. Home
  2. DAKT vs GERN Comparison

DAKT vs GERN Comparison

Compare DAKT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Daktronics Inc.

DAKT

Daktronics Inc.

HOLD

Current Price

$20.79

Market Cap

944.7M

Sector

Industrials

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.26

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAKT
GERN
Founded
1968
1990
Country
United States
United States
Employees
N/A
258
Industry
Office Equipment/Supplies/Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
944.7M
808.3M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
DAKT
GERN
Price
$20.79
$1.26
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$2.17
AVG Volume (30 Days)
231.4K
13.9M
Earning Date
03-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.75
N/A
Revenue
$608,932,000.00
N/A
Revenue This Year
$12.06
$26.91
Revenue Next Year
$9.16
$43.75
P/E Ratio
$27.29
N/A
Revenue Growth
6.89
N/A
52 Week Low
$13.05
$1.04
52 Week High
$28.27
$2.01

Technical Indicators

Market Signals
Indicator
DAKT
GERN
Relative Strength Index (RSI) 59.01 34.40
Support Level $18.76 $1.22
Resistance Level $21.14 $1.29
Average True Range (ATR) 0.55 0.06
MACD 0.14 -0.00
Stochastic Oscillator 89.72 21.15

Price Performance

Historical Comparison
DAKT
GERN

About DAKT Daktronics Inc.

Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: